During concurrent use , patients should contact their healthcare provider if they experience: Symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) Severe, persistent abdominal pain (often radiating to the back) with or without vomitingthis could indicate pancreatitis, a serious adverse effect associated with GLP-1 receptor agonists requiring urgent medical evaluation Unexplained fatigue, jaundice, or abdominal pain (potential liver concerns) Worsening gastrointestinal symptoms beyond typical semaglutide side effects New or unusual symptoms that may represent an adverse reaction Patients taking oral medications with a narrow therapeutic index should discuss timing and monitoring with their healthcare provider, as semaglutide's effect on gastric emptying may affect absorption

Understanding the potential mechanisms, management strategies, and warning signs that warrant medical attention is essential for both patients and healthcare professionals to optimise treatment outcomes whilst maintaining safety
Some continue longer for maintenance
This is the only oral weight loss medication that has approval in the UK to be sold over the counter
Available at: Accessed 9/28/18